Other

Cns-rheumatology, Inc.

Inmedix, Inc.

Andrew J. Holman

Andrew J Holman

Steven Ross Daly

Sunghyun Lee

Michael Glenn Loveless

Rade Gadzic

Portable electrocardiogram device with touchscreen display

The present invention provides methods for determining whether to provide an inhibitor of sympathetic nervous system activity to a human being suffering from an autoimmune disease and/or fibromyalgia. The methods of this aspect of the invention each include the steps of: (a) measuring the heart rate variability of a human being suffering from an autoimmune disease or fibromyalgia, to yield heart rate variability data; (b) analyzing the heart rate variability data to determine whether there is excessive sympathetic nervous system activity in the heart of the human being; and (c) providing an inhibitor of sympathetic nervous system activity to the human being if there is excessive sympathetic nervous system activity in the heart of the human being.

Methods for determining whether to provide an inhibitor of sympathetic nervous system activity to a human being suffering from an autoimmune disease or fibryomyalgia

The present invention is directed to methods for the treatment of human patients afflicted with fibromyalgia using a non-ergot dopamine receptor D2/D3 agonist. In particular, patients are treated with a therapeutically effective amount of tetrahydro-benzthiazole or 3(H)-indolone compounds that are dopamine agonists. More specifically, the compounds 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or 4-&lsqb;2-(dipropylamino)-ethyl&rsqb;-1,3-dihydro-2H-indol-2-one are administered to fibromyalgia patients to reduce the musculoskeletal pain symptoms associated with fibromyalgia.

Use of dopamine D2/D3 receptor agonists to treat fibromyalgia

The present invention is directed to metho s for the treatment of human patients afflicted with fibromyalgia using a non-ergot dopamine receptor D2/D3 agonist. In particular, patients are treated with a therapeutically effective amount of tetrahydro-benzthiazole or 3(H)-indolone compounds that are dopamine agonists. More specifically, the compounds 2-amino-6-n-propylamino-4,5,6,7-tetrahydrobenzo-thiazole or 4-&lsqb;2-(dipropylamino)-ethyl&rsqb;-1,3-dihydro-2H-indol-2-one are administered to fibromyalgia patients to reduce the musculoskeletal pain symptoms associated with fibromyalgia.

Growing community of inventors

Seattle, WA, United States of America

Andrew J Holman